secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001171843-25-004809
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika's Hyalofast Phase III misses co-primary endpoints; plans PMA filing by end of 2025
--------------------------------------------------------------------------------

- Hyalofast missed pre-specified co-primary endpoints (percent change in KOOS Pain and IKDC function vs microfracture) on statistical significance.
- Statistically significant improvements on secondary endpoints: KOOS Sports & Recreation, Quality of Life, and Total KOOS.
- Safety profile comparable to microfracture; company plans to file final PMA module in H2 2025.
- Over 35,000 patients treated outside U.S. since 2009; independent studies support safety and efficacy.
- Study impacted by higher dropout in microfracture arm and COVID-related missed visits, reducing evaluable sample size.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184325004809/0001171843-25-004809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184325004809/f8k_072925.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer